Cellectar Biosciences, Inc.
Clinical trials sponsored by Cellectar Biosciences, Inc., explained in plain language.
-
New hope for young brain cancer patients: targeted radiotherapy trial launches
Disease control OngoingThis early-stage study tests a new targeted radiotherapy (CLR 131) in 50 children, teens, and young adults (ages 10-25) with a type of brain cancer called high-grade glioma that has come back or not responded to treatment. The goal is to find the safest and most effective dose by…
Phase: PHASE1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New hope for kids with tough cancers: experimental drug CLR 131 enters human testing
Disease control OngoingThis early-stage study tests an experimental drug, CLR 131, in 30 children, adolescents, and young adults whose solid tumors, lymphoma, or brain tumors have returned or not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Research…
Phase: PHASE1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC